Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients

Lung Cancer

Volumn 72, Issue 2, 2011, Pages 238-243

  Han, Baohui ^a   Gao, Ge ^b   Wu, Wenting ^b   Gao, Zhiqiang ^a   Zhao, Xueying ^b   Li, Ling ^c,d   Qiao, Rong ^a   Chen, Hongyan ^b   Wei, Qingyi ^e   Wu, Jinchang ^f   Lu, Daru ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d FUDAN UNIVERSITY   (China)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NANJING MEDICAL UNIVERSITY   (China)

Author keywords

ABCC2; Non small cell lung cancer; Platinum; Polymorphisms; Response; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; NAVELBINE; PACLITAXEL;

ABCC2 GENE; ADULT; AGED; AGRANULOCYTOSIS; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; DNA POLYMORPHISM; FEMALE; GASTROINTESTINAL TOXICITY; GENE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; PLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; RISK FACTORS; SEX FACTORS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 79953796265     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.09.001     Document Type: Article

References (40)

1. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. International Journal of Cancer 1999, 80:827-841.
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
3. Spiro S.G., Silvestri G.A. The treatment of advanced non-small cell lung cancer. Current Opinion in Pulmonary Medicine 2005, 11:287-291.
4. Simon G.R., Wagner H. Small cell lung cancer. Chest 2003, 123:259S-271S.
5. Viktorsson K., De Petris L., Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochemical and Biophysical Research Communications 2005, 331:868-880.
6. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews 2007, 33:9-23.
7. Silvestri G., Pritchard R., Welch H.G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. British Medical Journal 1998, 317:771-775.
8. Suzuki H., Sugiyama Y. Transporters for bile acids and organic anions. Membrane Transporters as Drug Targets 1999, pp. 387-439.
9. Suzuki H., Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Advanced Drug Delivery Reviews 2002, 54:1311-1331.
10. Sai K., Saito Y., Itoda M., Fukushima-Uesaka H., Nishimaki-Mogami T., Ozawa S., et al. Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metabolism and Pharmacokinetics 2008, 23:139-147.
11. Schwabedissen H., Jedlitschky G., Gratz M., Haenisch S., Linnemann K., Fusch C., et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metabolism and Disposition 2005, 33:896-904.
12. Wu W.T., Zhang W., Qiao R., Chen D., Wang H.B., Wang Y., et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clinical Cancer Research 2009, 15:3889-3895.
13. Jurinke C., van den Boom D., Cantor C., Koster H. Automated genotyping using the DNA MassArray(tm) technology. Methods in Molecular Biology-Clifton then Totowa 2001, 170:103-116.
14. Stephens M., Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. American Journal of Human Genetics 2003, 73:1162-1169.
15. Sun N., Sun X., Chen B., Cheng H., Feng J., Cheng L., et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 2010, 65:437-446.
16. Itoda M., Saito Y., Soyama A., Saeki M., Murayama N., Ishida S., et al. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. Drug Metabolism and Disposition 2002, 30:363-364.
17. Taniguchi K., Wada M., Kohno K., Nakamura T., Kawabe T., Kawakami M., et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Research 1996, 56:4124-4129.
18. Han J.Y., Lim H.S., Yoo Y.K., Shin E.S., Park Y.H., Lee S.Y., et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007, 110:138-147.
19. Ufer M., Mosyagin I., Muhle H., Jacobsen T., Haenisch S., Hsler R., et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C> T polymorphism in young and adult patients with epilepsy. Pharmacogenetics and Genomics 2009, 19:353.
20. Haenisch S., Zimmermann U., Dazert E., Wruck C.J., Dazert P., Siegmund S., et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics Journal 2007, 7:56-65.
21. Zhang Y., Zhao T., Li W., Vore M. The 5'-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation. Molecular Pharmacology 2010, 77:237-246.
22. Haenisch S., May K., Wegner D., Caliebe A., Cascorbi I., Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenetics and Genomics 2008, 18:357.
23. Liedert B., Materna V., Schadendorf D., Thomale J., Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G(2)-arrest in melanoma cells resistant to cisplatin. Journal of Investigative Dermatology 2003, 121:172-176.
24. Sohn J., Lee S., Lee S., Kim E., Cha S., Kim C., et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Japanese Journal of Clinical Oncology 2006, 36:137.
25. Chen S, Huo X, Lin Y, Ban H, Li W, Zhang B, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. International Journal of Hygiene and Environmental Health 213:140-5.
26. Pan J., Han J., Wu J., Huang H., Yu Q., Sheng L. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 2008, 78:49-55.
27. Hoffmann K., Lscher W. Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR-Rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia 2007, 48:631-645.
28. De Jong F., Scott-Horton T., Kroetz D., McLeod H., Friberg L., Mathijssen R., et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clinical Pharmacology and Therapeutics 2007, 81:42-49.
29. Han J., Lim H., Park Y., Lee S., Lee J. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 2009, 63:115-120.
30. Kiyotani K., Mushiroda T., Kubo M., Zembutsu H., Sugiyama Y., Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Science 2008, 99:967-972.
31. Sai K., Saito Y., Maekawa K., Kim S., Kaniwa N., Nishimaki-Mogami T., et al. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemotherapy and Pharmacology 2010, 66:95-105.
32. Innocenti F., Undevia S., Iyer L., Xian Chen P., Das S., Kocherginsky M., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Journal of Clinical Oncology 2004, 22:1382-1388.
33. Schwartz J.B. The influence of sex on pharmacokinetics. Clinical Pharmacokinetics 2003, 42:107-121.
34. Singh S., Parulekar W., Murray N., Feld R., Evans W., Tu D., et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. Journal of Clinical Oncology 2005, 23:850.
35. Kimchi-Sarfaty C., Oh J., Kim I., Sauna Z., Calcagno A., Ambudkar S., et al. A " silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525.
36. Nackley A., Shabalina S., Tchivileva I., Satterfield K., Korchynskyi O., Makarov S., et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314:1930.
37. Sauerbruch A., Lammert F. Association of the c. 3972C 1T variant of the multidrug resistance-associated protein 2 gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 2009, 80:36-39.
38. Strange R., Spiteri M., Ramachandran S., Fryer A. Glutathione-S-transferase family of enzymes. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2001, 482:21-26.
39. Haimeur A., Conseil G., Deeley R., Cole S. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Current Drug Metabolism 2004, 5:21-54.
40. Suk R., Gurubhagavatula S., Park S., Zhou W., Su L., Lynch T., et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clinical Cancer Research 2005, 11:1534.